The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization
Open accessAbstract
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9), 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR), cholesteryl ester transfer protein (CETP) and apolipoprotein C3 (APOC3) are pivotal regulators of lipid metabolism, with licensed drugs targeting these genes. The use of lipid-lowering therapy via the inhibition of these genes has demonstrated a reduction in the risk of cardiovascular disease. However, concerns persist regarding their potential long-term impact on aortic diseases and calcific aortic valve disease (CAVS). This study aims to investigate causal relationships between genetic variants resembling these genes and aortic disease, as well as calcific aortic valve disease using Mendelian randomization (MR). Methods: We conducted drug-target Mendelian randomization employing summary-level statistics of low-density lipoprotein cholesterol (LDL-C) to proxy the loss-of-function of PCSK9, HMGCR, CETP and APOC3. Subsequently, we investigated the association between drug-target genetic variants and calcific aortic valve stenosis and aortic diseases, including thoracic aortic aneurysm (TAA), abdominal aortic aneurysm (AAA), and aortic dissection (AD). Results: The genetically constructed variants mimicking lower LDL-C levels were associated with a decreased risk of coronary artery disease, validating their reliability. Notably, HMGCR inhibition exhibited a robust protective effect against TAA (odds ratio (OR): 0.556, 95% CI: 0.372–0.831, p = 0.004), AAA (OR: 0.202, 95% CI: 0.107–0.315, p = 4.84 × 10-15), and AD (OR: 0.217, 95% CI: 0.098–0.480, p = 0.0002). Similarly, PCSK9, CETP and APOC3 inhibition proxies reduced the risk of AAA (OR: 0.595, 95% CI: 0.485–0.730, p = 6.75 × 10-7, OR: 0.127, 95% CI: 0.066–0.243, p = 4.42 × 10-10, and OR: 0.387, 95% CI: 0.182–0.824, p = 0.014, respectively) while showing a neutral impact on TAA and AD. Inhibition of HMGCR, PCSK9, and APOC3 showed promising potential in preventing CAVS with odds ratios of 0.554 (OR: 0.554, 95% CI: 0.433–0.707, p = 2.27 × 10-6), 0.717 (95% CI: 0.635–0.810, p = 9.28 × 10-8), and 0.540 (95% CI: 0.351–0.829, p = 0.005), respectively. However, CETP inhibition did not demonstrate any significant benefits in preventing CAVS (95% CI: 0.704–1.544, p = 0.836). The consistency of these findings across various Mendelian randomization methods, accounting for different assumptions concerning genetic pleiotropy, enhances the causal inference. Conclusions: Our MR analysis reveals that genetic variants resembling statin administration are associated with a reduced risk of AAA, TAA, AD and CAVS. HMGCR, PCSK9 and APOC3 inhibitors but not CETP inhibitors have positive benefits of reduced CAVS. Notably, PCSK9, CETP and APOC3 inhibitors exhibit a protective impact, primarily against AAA, with no discernible benefits extending to TAA or AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Recent studies together with ours using different IVs construction strategy have all identified the protective role of PCSK inhibitor on CAVS46–48, which further confirmed the validity of our finding.”
From Genetic insights into causal effects of lipids and lipid-modifying targets on calcific aortic valve stenosis: a Mendelian randomized study (2025) · cites this paper as [47]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019
Roth, G. A., Mensah, G. A., Johnson, C. O., Addolorato, G., Ammirati, E., Baddour, L. M., Barengo, N. C., Beaton, A. Z., Benjamin, E. J., Benziger, C. P., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.11.010 · Cited by 11,449 · cited 1×
“In 2019, a total of 172,000 deaths were attributed to aortic aneurysms [4], encompassing both TAA and AAA, reflecting a concerning trend driven by population growth and aging.”
BackgroundBowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 1×
“If the intercept term equals zero precisely, the MR-Egger estimate aligns with the IVW estimate [34].”
MethodBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922 · cited 1×
“Median weighting, which assesses whether the majority of genetic variants are associated with the outcomes, was performed as part of sensitivity analysis [33].”
BackgroundVerbanck, M., Chen, C.-Y., Neale, B., & Do, R. (2018) · Nature Genetics · doi:10.1038/s41588-018-0099-7 · Cited by 8,591 · cited 1×
“MR-PRESSO, meanwhile, was utilized to automatically detect potential outliers and remove SNPs exhibiting potential pleiotropy [35].”
MethodEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138 · cited 1×
“Phase 3 clinical trials have demonstrated their beneficial effects in treating high-cardiovascular-risk patients [45].”
BackgroundMendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Lawlor, D. A., Harbord, R. M., Sterne, J. A. C., Timpson, N., & Davey Smith, G. (2008) · Statistics in Medicine · doi:10.1002/sim.3034 · Cited by 4,618 · cited 1×
“The IVW method furnishes a summary estimate of the causal effect of exposure on the outcome by amalgamating estimates from each SNP, with weights determined by the inverse of each instrument’s effect estimate variance [32].”
MethodInterpreting findings from Mendelian randomization using the MR-Egger method.
Burgess, S., & Thompson, S. G. (2017) · European Journal of Epidemiology · doi:10.1007/s10654-017-0255-x · Cited by 4,571
FinnGen provides genetic insights from a well-phenotyped isolated population
Kurki, M. I., Karjalainen, J., Palta, P., Sipilä, T. P., Kristiansson, K., Donner, K. M., Reeve, M. P., Laivuori, H., Aavikko, M., Kaunisto, M. A., et al. (2023) · Nature · doi:10.1038/s41586-022-05473-8 · Cited by 4,233 · cited 1×
“Summary-level data of aortic diseases and CAVS were extracted from the latest R9 release of the FinnGen GWAS results [30].”
MethodWiller (2013) · doi:10.1038/ng.2797 · Cited by 2,983 · cited 1×
“Summary statistics for LDL-C were sourced from the Global Lipids Genetics Consortium (GLGC), which conducted a case-control GWAS meta-analysis encompassing 173,082 individuals from 60 studies [28].”
MethodA comprehensive 1000 Genomes–based genome-wide association meta-analysis of coronary artery disease
the CARDIoGRAMplusC4D Consortium (2015) · Nature Genetics · doi:10.1038/ng.3396 · Cited by 2,447
Cited by
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 51
Wu, C., Pu, Q., Zou, Y., Jin, J., Lei, Y., Hu, Y., Chen, Z., & Yu, L. (2025) · Scientific Reports · doi:10.1038/s41598-025-15525-4 · Cited by 3
The two faces of cholesteryl ester transfer protein inhibitors
Pirillo, A., & Catapano, A. L. (2025) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000001017 · Cited by 2
Genetically predicted high-density lipoprotein traits and pan-disease risk: a systematic review
Wu, J., Su, B., Fan, Z., & Zhan, H. (2026) · Epidemiologic Reviews · doi:10.1093/epirev/mxag001 · Cited by 1
Hou, J., Lin, L., Huang, J., Chai, Q., Wang, S., Liu, X., & Liu, Q. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177838 · Cited by 2
Metadata
- Authors
- Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P.
- Affiliations
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking University (CN)
- Corresponding author
- Wen, Jianyan
- Liu, Peng
- Venue
- Reviews in Cardiovascular Medicine
- Publisher
- IMR Press
- Published
- 2024-08-19
- Volume
- 25
- Issue
- 8
- Pages
- 292-292
- ISSN
- 1530-6550 (ISSN-L)
- 2153-8174
- PMC
- PMC11367000
- OpenAlex
- W4402012467
- Cited by
- 6
- References
- 59
- Citations by year
- 2026: 3 · 2025: 3
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Reviews in Cardiovascular Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Natural Science Foundation of China (82270443, 82170066, 81670275, 81670443)
- National High Level Hospital Clinical Research Funding (2022-NHLHCRF-ZSYX-01)
- International S&T cooperation program (2013DFA31900)
- Major New Drug Creation Special Project, Ministry of Science and Technology of the People’s Republic of China (2020ZX09201-012)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Immunology and Microbiology › Immunology › Atherosclerosis and Cardiovascular Diseases
- Keywords
- calcific aortic stenosis, aortic disease, thoracic aortic aneurysm, abdominal aortic aneurysm, aortic dissection, PCSK9, HMGCR, cholesteryl ester transfer protein, apolipoprotein C-III, lipid-lowering drugs, LDL cholesterol, coronary artery disease, causal relationship, statins, ezetimibe
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization. https://app.cochat.ai/papers/10.31083/j.rcm2508292
- The paper
- Yang, L., Xu, M., Gao, X., Liu, J., Zhang, D., Zhang, Z., Ye, Z., Wen, J., & Liu, P. (2024). Causal Relationships between Lipid-Lowering Drug Target and Aortic Disease and Calcific Aortic Valve Stenosis: A Two-Sample Mendelian Randomization. Reviews in Cardiovascular Medicine. https://doi.org/10.31083/j.rcm2508292
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.